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1. Introduction 
Exposure to xenobiotics induces complex biochemical responses in mammalian cells 
resulting in several perturbations in cellular toxicity pathways. Within the context of 
systems biology, such biochemical perturbations can be studied individually using “omics” 
approaches such as toxicogenomics, transcriptomics, proteomics and metabolomics (Heijne 
et al., 2005). The objective of this chapter is to examine how the metabolomics approach can 
be used in identifying the risk posed by environmental chemicals to human health using 
selective examples of organ toxicity. Metabolomics is a medium-to-high throughput 
technique employing predominantly mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) technology (Roux et al., 2011) for the identification and characterization of 
endogenous metabolites of low molecular weight (<1800 Da) arising from different 
biochemical pathways either as primary or secondary metabolites (Idle & Gonzalez, 2007). 
The sum total of all small metabolites is referred to as the “metabolome”. Metabolomics has 
also been applied to the identification of low molecular weight, exogenous metabolites of 
xenobiotics (Roux et al., 2011; Rubino et al., 2009). With these capabilities, metabolomics 
represents a relatively quick and informative approach for assessing the physiological 
response to environmental chemicals.  
2. Human health risk assessment 
Chemicals in the environment could pose potential risks to human health. In order to inform 
the assessment of risks from chemical exposures, the U.S. National Research Council (NRC) 
published a report entitled, “Risk Assessment in the Federal Government: Managing the Process,” 
more commonly known as the “Red Book” (NRC, 1983), which has been widely accepted 
and endorsed by the U.S. Environmental Protection Agency (U.S. EPA) and other federal 
agencies. This risk assessment process consists of four steps: hazard identification, dose-
response assessment, exposure assessment, and risk characterization. The focus herein is on 
hazard identification, which has been defined as “identification of the contaminants that are 
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suspected to pose health hazards, quantification of the concentrations at which they are 
present in the environment, a description of the specific forms of toxicity (i.e. neurotoxicity, 
carcinogenicity, etc.) that can be caused by the contaminants of concern, and an evaluation 
of the conditions under which these forms of toxicity might be expressed in exposed 
humans” (NRC, 1994).  
For human health assessment of chemicals, non-cancer or cancer risk values are derived 
based on the selection of a critical endpoint of toxicity or several endpoints (e.g. biochemical, 
pathological, physiological, and behavioral abnormalities) of adverse health outcomes. 
Uncertainty factors are applied to the lowest dose associated with the critical health 
outcome(s) in order to derive the resulting exposure level for non-cancer toxicity. These 
uncertainty factors attempt to account for exposure duration, pharmacokinetic, and 
pharmacodynamic data gaps associated with inter- and intra-species extrapolation. 
The U.S. EPA and the International Agency for Research on Cancer (IARC) evaluate the 
evidence for carcinogenesis in humans from epidemiological, experimental animal, and 
mechanistic data to determine the qualitative cancer classification for humans. In addition, 
the U.S. EPA evaluates exposure-response relationships and develops quantitative cancer 
risk values based on the observed tumors that correspond to a unit exposure (U.S. EPA, 
2005). Uncertainties with cancer risk values are presented and are generally associated with 
the mode of action (MOA) for carcinogenicity.  
One of the major concerns with cancer risk assessment is false-positive animal tumor 
findings. Having an understanding of the mechanism(s) leading to carcinogenicity would 
help in developing a better perspective of whether a carcinogen in experimental animals is 
likely to be a carcinogen in humans. For example, correlating a metabolomic profile of a 
suspected carcinogen between human exposures (environmental or occupational) and 
experimental animal exposure studies would be highly useful. If similar biochemical 
markers were to appear across the human and animal metabolomic profiles, that 
information would help in informing similarities or differences in interspecies mechanisms. 
Further, if the chemical was demonstrated to be a carcinogen in animals through a 
traditional two-year animal bioassay, but there was inconclusive epidemiological evidence, 
the similarity in metabolomic data could be used along with other mechanistic data (e.g. 
mutagenicity/genotoxicity assays, cell proliferation findings, oxidative stress, epigenetics, 
etc.) to support or refute human carcinogenicity. In this regard, metabolomics information 
could be used to support mechanistic data to augment the animal and human findings.  
3. The potential of “omics” data to inform mode of action of environmental 
chemicals 
In developing a human health evaluation for environmental chemical hazard 
identification, it is ideal to have information on the key mechanistic events leading to an 
adverse health outcome. In this regard, mode of action (MOA) is an important part of 
hazard identification. MOA can be defined as “a sequence of key events and processes, 
starting with interaction of an agent with a cell, proceeding through operational and 
anatomical changes, and resulting in cancer formation” (U.S. EPA, 2005). A ‘key event’ is 
defined as “an empirically observable precursor which is by itself a necessary component 
of the MOA or is a biologically-based measurable marker for such a component” (U.S. 
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EPA, 2005). In vitro systems (e.g. cell cultures) and in vivo models (e.g. experimental 
animals or human population studies) have identified several of the early key events 
such as oxidative stress, inflammation, genotoxicity, and cytotoxicity that occur from 
toxicant exposure. Since metabolomics measures biological response at the molecular 
level, this approach can identify the metabolites associated with the sequence of ‘key 
events’ and the processes inherent to the mechanism(s) of xenobiotic toxicity. The 
metabolomics approach could generate several mode(s) of action hypotheses using a 
nontargeted approach. The individual MOA hypothesis thus generated could be tested 
in targeted approaches (e.g. measuring glutathione reduction from oxidative stress) 
using more conventional assays. Metabolomics data could be used to further inform the 
mode(s) of action in experimental animals associated with carcinogenicity or with non-
cancer health outcomes, which may help to confirm the relevancy of the observations in 
experimental animals to humans.  
4. Metabolomics approach in investigating environmental chemical exposure 
Environmental chemicals act through multiple toxicity pathways via a multitude of 
mechanisms (Guyton et al., 2009). To date, very limited toxicogenomics information has 
been applied to the field of risk assessment (Boverhof & Zacharewski, 2006; Mortensen & 
Euling, 2011). There is a paucity of relevant metabolomic information for application to 
human health risk assessment of environmental chemicals. To date, the available literature 
suggests an informative role of metabolomics in understanding the mode of action of 
environmental xenobiotics (Vulimiri et al., 2011; Vulimiri et al., 2009). 
In general, human data are relatively sparse for many environmental chemicals with respect 
to both non-cancer and cancer health outcomes. Most human data are occupational, where 
exposure levels are generally higher than those encountered in the environment. In many 
cases, there are not any environmental or occupational human exposures that could be used 
to corroborate the animal data. In these cases, animal data are generally used to develop 
non-cancer and cancer risk values for human health assessments thereby raising issues of 
uncertainty associated with interspecies extrapolation. Metabolomic data could be used to 
fill in such data gaps. For example, in vitro metabolomic assays with human cells may be 
developed to compare with animal metabolomic profiles to determine if there are 
potentially similar mechanisms of toxicity or for identifying toxicity pathways. As a result, 
this characterization of biochemical mechanisms of toxicity would inform hazard 
identification for use in the human health risk assessment process.  
5. Ability of metabolomics to differentiate gender, phenotypic, and genetic 
differences, and organ-specific effects 
Since metabolomics analyzes endogenous and exogenous (xenobiotic-derived) low 
molecular weight metabolites, this approach has been applied to the differentiation of 
metabolic profiles between phenotypes and genotypes. As briefly discussed below, 
metabolomics has the ability to inform gender, genetic, and phenotypic differences as well 
as organ-specific effects. For understanding the toxicity of environmental agents, the utility 
of such information would clarify toxicodynamic uncertainty associated with the 
extrapolation between species as well as within species (i.e. human) variability. 
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5.1 Gender differences 
Metabolomics approach can differentiate between gender-dependent differences in the 
metabolic profiles of untreated or control experimental animals. In a study aimed at the 
identification of novel biomarkers of effect using chemicals with diverse modes of action, 
one research group (van Ravenzwaay et al., 2007) pooled the metabolomic data (i.e. plasma 
profiles) from eleven individual experiments involving 670 male and female control Wistar 
rats over a span of one year. After principal component analysis (PCA), the authors found 
that the metabolic profiles were clustered into separate groups for males and females 
suggesting a stable metabolome of the control rats during the study period. This observation 
highlights the ability of metabolomics to potentially identify unique gender responses to 
chemical exposure. 
5.2 Genetic differences and phenotypic effects 
The metabolomics approach can be further used for studying the relationship between the 
genotype and phenotype of the organism. Genetic polymorphisms in human genes are 
known to modify exposure to environmental health hazards and are a source of 
uncertainty when assessing risk from environmental chemicals (Ginsberg et al., 2009; 
Kelada et al., 2003). Genetic differences have been shown to reflect changes in the 
metabolite profiles of individuals. In a human population, genetically determined variants 
(e.g. those associated with fatty acid metabolism) in metabolic phenotype (metabotype) 
have been identified by simultaneously detecting single-nucleotide polymorphisms 
(SNPs) in a genome-wide association study (GWAS) and endogenous serum metabolites 
(Gieger et al., 2008). 
This is also evident in the field of functional genomics where a change in phenotype is 
observed due to gene-related alterations (reverse-genetics) such as deletions or insertions 
leading to silent mutations as in yeasts (Raamsdonk et al., 2001). Specific gene mutations can 
also be evaluated using metabolic footprinting (Szeto et al., 2010). Such metabolomic data 
could provide basic information regarding gene product function, particularly in the context 
of environmental exposure. 
Also, the genotypes of animals, as in genetically manipulated animal models (e.g. gene 
knockout and transgenic mice), have been used effectively for understanding the 
metabolism of toxicants mediated by cytochrome P450 (CYP) isozymes, in order to further 
elucidate mechanisms of toxicity. For example, MS-based approaches were able to 
distinguish between the metabolic profiles for Cyp2e1-null, CYP1A2-humanized, and wild-
type mice after exposure to the ubiquitous dietary carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (Chen et al., 2007) or the hepatotoxic agent acetaminophen 
(Chen et al., 2008). As a result, the metabolomics approach could be used to identify 
mechanistic changes stemming from genetic differences. 
5.3 Organ-specific effects 
Metabolomics approach has been utilized in identifying specific profiles that are altered in 
different organs in response to toxicant injury. The following represents a brief discussion of 
three select organ toxicities associated with exposure to a given chemical or mixture of 
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chemicals. The extent of the metabolomic datasets varies for each type of organ toxicity; 
however, discussion focuses on how metabolomic investigations have contributed to some 
understanding of mechanisms of toxicity. Some of these metabolic changes are specific but 
many are nonspecific for the selected organ toxicities. 
5.3.1 Hepatotoxicity (Carbon tetrachloride) 
Carbon tetrachloride (CCl4) is a well-studied hepatotoxicant and carcinogen that has been 
used as a fumigant (Manibusan et al., 2007). The mechanisms underlying CCl4 toxic 
responses are fairly well understood. In rats, CCl4 exposure results in mild to severe 
centrilobular necrosis of the liver with elevation of serum alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) activities suggestive of hepatotoxicity. In addition, 
CCl4 induces lipid peroxidation, oxidative stress, and regenerative proliferation, eventually 
leading to hepatocarcinogenesis. The following brief discussion focuses on how 
metabolomics has been used to identify metabolites associated with these known 
mechanisms of toxic response. 
Metabolomic analyses have identified several aldehydes (e.g. formaldehyde, acetaldehyde, 
propanal, butanal, pentanal, hexanal and malondialdehyde) excreted in urine (De Zwart et 
al., 1997) or in exhaled breath (Gee et al., 1981) from rodents dosed with CCl4. Similarly, 
short-chain hydrocarbons (e.g. pentane and ethane) generated during lipid peroxidation 
have been reported in the breath of humans suggestive of CCl4-induced oxidative stress 
(Hwang & Kim, 2007). These reactive aldehydes arising from lipid peroxidation have been 
shown to be quenched by reduced glutathione (GSH), causing GSH depletion which leads to 
cirrhosis in the liver of rats (Cabre et al., 2000). Further, GSH depletion causes a perturbation 
of prooxidant-antioxidant balance eventually leading to oxidative stress (Ichi et al., 2009). 
Metabolomic studies have provided support that oxidative stress induced by CCl4 generates 
reactive oxygen species (ROS) capable of causing DNA damage as shown by an increase in 
8-oxodeoxyguanosine (8-oxodG) and malondialdehyde-deoxyguanosine (M1G) adducts 
(Beddowes et al., 2003). Also, lipid peroxidation products, such as 4-hydroxynonenal, can 
form etheno adducts, which are capable of inducing mutations in critical genes through 
base-pair substitutions (Barbin, 2000; Chung et al., 1999). 
Further, CCl4-induced oxidative stress inhibits energy metabolism as observed by changes 
in levels of Krebs cycle intermediates (i.e. citric acid, 2-oxoglutarate, and succinate), which 
has an overall effect on glutathione metabolism eventually leading to hepatotoxicity (Huang 
et al., 2008; Kim et al., 2008; Lin et al., 2009; Robertson et al., 2000). These earlier cellular 
perturbations further affect Ca+2 homeostasis, cause protein and phospholipid degradation, 
and potentially lead to cytotoxicity (Manibusan et al., 2007), apoptosis and necrosis of the 
liver tissue (Sun et al., 2001). Furthermore, membrane phospholipid degradation leads to the 
release of high levels of o-phosphoethanolamine, a well-known biomarker of cytotoxicity 
that can be detected using a metabolomic approach (Wang et al., 2009).  
CCl4 toxicity also leads to an inflammatory response characterized by the release of 
arachidonic acid, which is the precursor for a cascade of events leading to prostaglandin and 
leukotriene synthesis involving cyclooxygenases and lipoxygenases, respectively (Basu, 
2003), and other newer inflammatory biomarkers, such as resolvins, protectins, and 
maresins (Liu et al., 2009; Serhan, 2009). Following cytotoxicity, liver tissue undergoes 
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regenerative proliferation and activation of the urea cycle characterized by polyamine 
biosynthesis, the latter being a hallmark of cellular proliferation and differentiation (Heby, 
1981). Detection of increased levels of urea cycle metabolites such as putrescine, ornithine, 
spermine, and spermidine (Pegg et al., 1981) in CCl4–exposed rats by metabolomics 
approach gives an early indication of regenerative cell proliferation, which has been 
detected at a later stage of disease progression using conventional toxicity assays. 
Overall, metabolomics studies have identified important biomarkers for CCl4–induced 
toxicity including: aldehydes (lipid peroxidation); GSH/GSSG ratio (oxidative stress); 8-
oxodG, M1G, and etheno adducts (genotoxicity); o-phosphoethanolamine (cytotoxicity); 
arachidonic acid and prostaglandins (inflammation); and polyamines (regenerative cell 
proliferation), which are also observed in conventional assays (Vulimiri et al., 2011). This 
brief discussion further supports the use of metabolomics for investigating toxicity 
associated with environmentally related chemicals. 
5.3.2 Neurotoxicity (Methylmercury) 
Methylmercury is a chemical that was originally used as a fungicide for agricultural 
purposes in the early 20th century. In one of the earliest studies of methylmercury toxicity, 
occupational exposure to this chemical resulted in detriments in neurological functions in 
factory workers and changes in brain morphology with specificity to the cerebellar area. 
Additionally, in one of the most noted disasters in the 20th century, methylmercury exposure 
through consumption of fish was determined to be the causative agent for producing 
neurological deficits in fishermen and neurodevelopmental abnormalities in children in 
Minamata Bay, Japan (Ekino et al., 2007). 
Traditional approaches in hazard characterization have concluded that the most sensitive 
(critical) effect observed from methylmercury exposure is neurobehavioral changes in 
children [as reviewed in (U.S. EPA, 2005) and Agency for Toxic Substances and Disease 
Registry (ATSDR, 1999)]. An uncertainty that was highlighted in both of these human health 
assessment evaluations was that of pharmacodynamic variability in the human population. 
One approach to address pharmacodynamic variability is to have an understanding of the 
key mechanism(s) that results in the sensitive effect. There have been several reviews on the 
neurological mechanisms associated with methylmercury (Ekino et al., 2007; Myers et al., 
2009). One of the primary mechanisms associated with methylmercury neurotoxicity in both 
the adult and developing brain is cytotoxicity. Methylmercury has been demonstrated to 
induce oxidative stress in the nervous system. Additionally, in vitro studies have reported 
that methylmercury treatment results in apoptosis in glial cells, cerebellar granule cells, and 
in neuronal cell lines such as differentiated PC12 cells and neuroblastoma cells. 
Methylmercury exposure in rats has also resulted in apoptosis in the cerebellum as well as 
loss of astrocytes in monkeys. The cell death pathway for methylmercury has been highly 
characterized as reviewed recently (Ceccatelli et al., 2010). In summary, several studies have 
demonstrated that methylmercury induces caspase-dependent apoptosis in primary 
neuronal cell cultures and cell lines. 
Metabolomic analysis for methylmercury was conducted using an in vitro methodology 
proposed by the European Commission Joint Research Centre in 2008 (van Vliet et al., 2008). 
Dynamic reaggregating neuronal cultures prepared from 16-day old rat fetal telencephalon 
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were used for this analysis. The identified putative biomarkers were γ-aminobutyric acid 
(GABA), choline, glutamine, creatine, and spermine. The authors were able to speculate 
potential mechanisms of methylmercury from results of traditional biochemical assays 
(Eskes et al., 2002; Monnet-Tschudi et al., 1996) where the enzymatic activities of neuronal 
enzymes including glutamine synthesis, choline acetyltransferase, and glutamic acid 
decarboxylase were reported to be significantly decreased. In essence, the decreased levels 
of GABA and choline in the in vitro metabolomic study may help to explain these decreases 
in enzymatic activity which then leads to neuron-specific toxicity. This information 
correlates to the observed increases in apoptotic cell death associated with methylmercury. 
Similarly, the increased creatine levels that were reported from methylmercury treatment 
were correlated to gliosis (proliferation of astrocytes in the central nervous system) by the 
authors. Creatine is generally linked to brain osmoregulation (Bothwell et al., 2001) and 
increased creatine levels would lead to increased activity of glial cells that could result in 
gliosis. 
Thus, a very limited metabolomic dataset for methylmercury adds to the mechanistic profile 
of this compound and helps establish a temporality of the key events leading to cytotoxicity 
in the brain. In the case of using the metabolomic data for methylmercury, the observed 
changes in the neuronal metabolites provide supportive, early evidence of later stage events 
leading to brain cytotoxicity. Metabolomic data from in vivo studies or from incidental 
human exposure would demonstrate any pharmacodynamic differences and if so, how such 
differences could be quantified through the available data rather than the default use of 
uncertainty factors. 
5.3.3 Pulmonary toxicity (Cigarette smoke) 
Cigarette smoking is one of the major etiological reasons for pulmonary toxicity and lung 
cancer. Cigarette smoke contain at least 4000 chemicals from different chemical classes, of 
which at least 60 are well-established carcinogens in experimental animals (Hecht, 2006). 
Cigarette smoke has been shown to induce oxidative stress and an inflammatory response in 
lungs, and chronic exposure is known to cause cancer. While cigarette smoke is most 
deleterious to the smoker, environmental or passive exposure to smoke (i.e. second-hand 
smoke) can lead to adverse health effects to bystanders (U.S. EPA, 1992). Using the 
metabolomics approach in A549 human lung epithelial cells it has been shown that several 
biochemical pathways are altered by either the whole smoke (WS) or its component phases 
i.e. wet total particulate matter (WTPM) or gas/vapor phase (GVP) (Vulimiri et al., 2009). 
Exposures to the different phases lead to unique biochemical alterations in A549 cells. For 
example, WTPM exposure resulted in changes in the Krebs cycle and urea cycle metabolites, 
whereas GVP exposure resulted in alterations in hexosamines and in lipid metabolism. 
These investigators found that exposure to cigarette smoke was associated with 
perturbations in the metabolism of glutathione, amino acids, lipids, and nucleotides. 
Alterations were also seen in the urea cycle, Krebs cycle, and the production of polyamines 
and cellular cofactors. 
Oxidative stress is an important consequence associated with cigarette smoke. The oxidants 
produced or found in cigarette smoke can react with and damage cellular macromolecules 
including proteins, DNA, and lipid membranes. Additionally, these oxidants can act as 
signaling molecules that can influence cell proliferation (Faux et al., 2009). However, cells 
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contain antioxidant defenses, such as GSH to prevent oxidative damage (Rahman & 
MacNee, 1999). The metabolomics approach has indeed found changes in metabolites 
associated with these effects of cigarette smoke. Predominant changes in metabolites from 
exposure to WS included glutathione and -glutamylglutamine, which showed 51 and 13-
fold increases compared to control cells. The increased levels of metabolites within the 
glutathione pathway (i.e. glutathione and -glutamylglutamine) suggest a protective 
response against oxidative stress, which can result from WS. These data correlate with 
human microarray data that demonstrated an antioxidant response to cigarette smoke 
through the induction of genes associated with glutathione metabolism (Spira et al., 2004). 
Further, Vulimiri and colleagues (Vulimiri et al., 2009) observed increased levels (16.4-fold) 
of o-phosphoethanolamine, a marker of phospholipid degradation that may indicate cell 
membrane damage. Additional observations included increased arachidonic acid levels that 
may suggest an inflammatory response and markers (e.g. putrescine) of cell proliferation. 
Conversely, there was a statistically significant decrease in glutathione levels from exposure 
to WTPM and GVP when compared to controls. Predominant metabolite changes in these 
phases were acetylcarnitine (4.5-fold increase) and palmitoleate (5.2-fold increase) for 
WTPM and GVP, respectively, both of which indicated changes in lipid metabolism 
(Vulimiri et al., 2009). In summary, these authors (Vulimiri et al., 2009) demonstrated how 
metabolomics could differentiate metabolic responses caused by exposure to complex 
mixtures (i.e. cigarette smoke) and also provided empirical data for metabolic changes for 
known markers of toxicity (e.g. decreased GSH, membrane damage) associated with 
exposure to cigarette smoke. 
6. Integrating “omics” data into risk assessment 
The field of toxicology is advancing with several of the high throughput screening 
techniques taking major roles in understanding toxicity pathways. More specifically 
toxicogenomics and proteomics have contributed to identifying the mechanisms of toxicity 
pathways (Burchiel et al., 2001; Heijne et al., 2005). Integration of data from different 
“omics” approaches would help clarify the mode of action of xenobiotics especially at low 
dose levels, which are relevant to environmental exposures. Thus, combining “omic” 
techniques such as toxicogenomics, transcriptomics, proteomics, and metabolomics 
promises to provide a robust understanding of biological responses to xenobiotics. Under 
this paradigm, effects on genes and their downstream products, namely proteins and the 
metabolites produced by proteins, can be assessed together. Researchers have utilized 
diverse “omics” approaches to understand the mode(s) of action or mechanism of different 
toxicity pathways in various experimental models. Some studies have indeed shown a good 
correlation between the genomics and metabolomics approaches. For example, 
metabolomics approach has demonstrated alterations in the pathways associated with lipid 
peroxidation, DNA damage and repair, and cell proliferation in rats exposed to CCl4 which 
was consistent with the expression of transcripts associated with steatosis/fibrosis that were 
specific to cell injury and regeneration (Chung et al., 2005a; Chung et al., 2005b; 
Fountoulakis et al., 2002). Additionally, metabolomics has identified biochemical alterations 
in pathways associated with oxidative stress, inflammation, cell proliferation, and 
cytotoxicity in human lung epithelial cells exposed to cigarette smoke (Vulimiri et al., 2009). 
These observations are supported by data from genomic (Harvey et al., 2007; Meng et al., 
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2006; Spira et al., 2004) and proteomic (Carter et al., 2011; Kelsen et al., 2008; Zhang et al., 
2008) investigations that also detected markers associated with the pathways affected by 
exposure to cigarette smoke.  
Conversely, the integration of “omics” technologies has also demonstrated some limitations. 
For example, a study by Steiling and co-workers found a discrepancy between genomic and 
proteomic data. Specifically, gel electrophoresis followed by LC-MS analysis identified 41 
proteins whose expression would not have been detected by microarray analysis (Steiling et 
al., 2009). Such data highlight the importance of assessing more downstream markers (i.e. 
proteins or metabolites) that may provide a more accurate understanding of the biological 
responses to chemical exposures. 
7. Shift in the risk assessment paradigm from apical endpoints to 
biochemical perturbations 
Historically, human health risk assessment relied on identifying apical endpoints, defined as 
“observable outcomes in a whole organism, such as a clinical sign or pathologic state, 
indicative of a disease state that can result from exposure to a toxicant”, such as birth 
defects, neurologic deficits, and tumor number that are obtained from high-dose animal 
bioassays (Krewski et al., 2010). However, the mechanistic relevance of these data can be 
tenuous considering the need for interspecies extrapolation and that environmental 
exposures may be orders of magnitude lower. Recently, the NRC report on “Toxicity Testing 
in the 21st Century: A Vision and Strategy” suggested a fundamental change in the risk 
assessment paradigm where the reliance on apical endpoints of toxicity would be replaced 
in favor of in vitro toxicity testing for identifying perturbations in biochemical pathways. 
Such an approach would employ cell lines, particularly human-based lines, and high 
throughput screening assays (e.g. genomics, proteomics) with computational toxicology 
methods. As a result, this approach would also lead to an overall increase in the efficiency of 
toxicity testing and decrease in animal usage [as reviewed in (Krewski et al., 2010)]. As 
pointed out by the NRC committee, the use of these low-dose, human-based in vitro systems 
would negate concerns associated with high-dose, animal data. Since metabolomics can 
identify early perturbations in biochemical pathways, this technology is poised to become 
an important element of this proposed risk assessment paradigm. 
8. Advantages of metabolomics approach for environmental chemical 
assessment 
Metabolomics approach offers several advantages for understanding the mechanisms of 
toxicity of environmental chemicals and informing human health assessments. One 
advantage of the metabolomics approach is the relatively non-invasive (e.g. urine samples) 
nature of this technique. In this context, samples from humans subjected to an incidental 
environmental exposure can be easily collected, analyzed, and correlated to metabolomic 
profiles from animal studies in order to identify critical effects from the exposure. Aside 
from quantitative differences, metabolic pathways are evolutionally conserved across 
different species; metabolomics data can be qualitatively extrapolated or interpreted at the 
molecular level among and between species. Unlike genomics and proteomics, 
metabolomics databases offer information on the structural, physicochemical, 
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pharmacological and spectral profiles as well as biological functions of metabolites (Go, 
2010). From a technical standpoint, sample preparation is relatively minimal for 
metabolomic analyses compared to genomics and proteomics approaches. Also, since 
metabolomics allows for the a priori selection of metabolites, the investigator has better 
control over the number of standards that need to be procured or synthesized for analysis. 
A survey of the available literature already demonstrates the value of using 
metabolomics for elucidating the mode of action of environmental chemicals. Since a 
number of matrices are amenable to metabolomic analysis, various systems including in 
vitro and in vivo models can be employed to identify metabolic perturbations associated 
with exposure to environmental chemicals. Some of the mammalian in vitro systems 
involved exposing A549 human lung carcinoma cells to cigarette smoke (Vulimiri et al., 
2009), human embryonic stem cells to various teratogens (West et al., 2010), and 
reaggregating neuronal cultures to methylmercury (van Vliet et al., 2008). From in vivo 
studies, intact organs from exposed experimental animals have been evaluated to include 
the analysis of intact lung after intratracheal instillation of silica dust (Hu et al., 2008) as 
well as liver and lung after exposure to 1-nitronaphthalene (Azmi et al., 2005). Also, 
metabolomics has been able to demonstrate different metabolic responses between 
mixtures of environmental chemicals. For example, in assessing the inflammatory 
response, Schmelzer et al (2006) found unique lipid profiles between rats exposed to 1-
nitronaphthalene and those exposed to a mixture of 1-nitronaphthalene and ozone. As 
highlighted earlier in this chapter, metabolomics approach has been shown to 
differentiate the metabolic changes attributed to the complex mixtures of whole smoke 
versus its two constituent physical phases (Vulimiri et al., 2009). 
9. Limitations of metabolomics research 
Regardless of whether a chemical being investigated is a pharmaceutical or environmental 
pollutant, a critique of metabolomics has been the detection of metabolites that appear to 
be changed independent of the toxicant, its mode of action, and target tissue. Such 
common metabolites were previously termed the “usual suspects” by Robertson and often 
include 2-oxoglutarate, citrate, succinate, and trimethyl amine/trimethyl amine oxide 
(Robertson, 2005). From a data interpretation standpoint, these “usual suspects” may 
confound the identification of metabolites that have true value as specific markers of 
organ toxicity by skewing results from pattern separation analyses (Connor et al., 2004; 
Robertson, 2005). Connor et al (2004) found that urinary metabolite changes, including 
many of the “usual suspect” metabolites, can be associated with systemic or secondary 
toxicity effects, namely reductions in food intake and body weight. Additionally, the 
authors suggest that such metabolites may still inform mechanisms of toxicity when put 
into the context of diet and weight change. Conversely, the authors did identify exposures 
where common metabolites were specific for toxicant exposure. For example, succinate 
and 2-oxoglutarate were specifically associated with exposure to the hepatotoxicant α-
naphthylisothiocyanate, rather than resulting from secondary toxicity (Connor et al., 
2004). Research by other investigators has identified metabolites as novel biomarkers 
associated with specific diseases and for specific toxicities. For example, 5-oxoproline has 
been demonstrated to be a specific marker of bromobenzene-induced hepatotoxicity 
(Waters et al., 2006). 
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10. Future directions/research needs 
A goal of this chapter has been to highlight how metabolomics approach can be used to 
better understand the toxicity of environmental chemicals, with a particular focus on hazard 
identification and mode of action. However, due to its relative infancy compared to 
conventional toxicity assays and other “omic” technologies, metabolomic information for 
environmental chemicals is sparse. As interest in metabolomics increases and as this 
approach becomes more accessible to researchers focused on environmental chemicals, this 
database will grow. A contemporary issue regarding xenobiotics is the influence of the 
microbiome on immunity, metabolism, and human health [reviewed in (Han et al., 2010)]. 
This microbiome involves the sum of all the microorganisms (e.g. bacteria) that internally 
and externally reside on an individual or animal. Of these microorganisms, the gut 
microbiota has been shown to influence the metabolism of several xenobiotics. Accordingly, 
the microbiome is likely to be important in the toxicity of environmental chemicals and 
pertinent to human health assessments (Betts, 2011). Thus, the influence of the microbiome 
is an important aspect of chemical toxicity that should be further studied using 
metabolomics.  
11. Conclusions 
Metabolomics is an emerging medium-to-high throughput technique which measures the 
endogenous biochemicals affecting different metabolic pathways and can be useful in 
characterizing the hazards of environmental chemicals. Identifying metabolic perturbations 
caused in mammalian cell systems following chemical exposure helps in elucidating the 
predominant toxicity pathways. Some of the advantages of using metabolomic data for 
hazard identification—one of the key steps in risk assessment—include the ability to inform 
gender, genetic, and organ-specific effects in a relatively expedient manner. As briefly 
discussed, metabolomics can identify early biochemical perturbations associated with 
toxicity in the hepatic, nervous, and pulmonary systems caused by selected environmental 
chemicals. As surveyed, various research systems using metabolomics demonstrate how 
metabolomic data could be used for hazard identification and mode of action 
characterization for environmental chemicals. Overall, metabolomics represents an 
opportunity to develop a better understanding of the toxicity of environmental chemicals 
and could further impact the human health assessment of these chemicals.  
12. Disclaimer 
The views expressed in this chapter are those of the authors and do not necessarily represent 
the views or policies of the U.S. Environmental Protection Agency. 
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